Conference Coverage
Novel psoriasis biologic wows with jaw-dropping results
Key clinical point: Up to 66 months after receiving a single subcutaneous injection of a biologic agent that selectively blocks interleukin-23,...
AT THE EADV CONGRESS
Key clinical point: Up to 66 months after receiving a single subcutaneous injection of a biologic agent that selectively blocks interleukin-23,...
Key clinical point: The interleukin-23 inhibitor BI 655066 outperformed ustekinumab and generated no concerning safety signals in a small phase II...